Caitong International Asset Management’s Candel Therapeutics CADL Stock Holding History

Caitong International Asset Management’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$57.3K	Buy	5,562 +5,393	+3,191%	+$40.7K	0.01%	684
2026 Q1	$828	Buy	169 +168	+16,800%	+$914	﹤0.01%	1493
2025 Q4	$6	Buy	+1	New	+$5	﹤0.01%	1814
2025 Q3	–	Sell	-2,261	Closed	-$11.4K	–	1995
2025 Q2	$11.4K	Buy	2,261 +1,890	+509%	+$9.73K	0.01%	669
2025 Q1	$2.1K	Buy	371 +40	+12%	+$327	﹤0.01%	1315
2024 Q4	$2.87K	Buy	+331	New	+$1.96K	﹤0.01%	1121

Other funds holding CADL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Caitong International Asset Management's CADL Position: Q2 2026 in Review

Caitong International Asset Management increased its Candel Therapeutics (CADL) stake by 3,191% in Q2 2026, buying an estimated $40.7K and bringing the position to 5,562 shares worth $57.3K. The position accounts for 0.01% of the portfolio, ranked #684.

Caitong International Asset Management first reported a position in CADL in Q4 2024 and has held it in 6 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

Caitong International Asset Management held 5,562 shares of Candel Therapeutics worth $57.3K as of Q2 2026.
Caitong International Asset Management bought 5,393 Candel Therapeutics shares in Q2 2026, an estimated $40.7K.
Candel Therapeutics made up 0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #684 holding.
Caitong International Asset Management first reported a position in Candel Therapeutics in Q4 2024 and has held it in 6 quarters since.
138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.